Cetera Investment Advisers
TVTX icon

Cetera Investment Advisers’s Travere Therapeutics TVTX Stock Holding History

Cetera Investment Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$288K Buy
9,677
+12
+0.1% +$359 ﹤0.01% 4021
2025
Q4 		$369K Buy
+9,665
New +$314K ﹤0.01% 3713

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cetera Investment Advisers's TVTX Position: Q1 2026 in Review

Cetera Investment Advisers increased its Travere Therapeutics (TVTX) stake by 0.12% in Q1 2026, buying an estimated $359 and bringing the position to 9,677 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #4021.

Cetera Investment Advisers first reported a position in TVTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $369K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Cetera Investment Advisers held 9,677 shares of Travere Therapeutics worth $288K as of Q1 2026.
  • Cetera Investment Advisers bought 12 Travere Therapeutics shares in Q1 2026, an estimated $359.
  • Travere Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q1 2026, its #4021 holding.
  • Cetera Investment Advisers first reported a position in Travere Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Cetera Investment Advisers's Travere Therapeutics position peaked at $369K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Cetera Investment Advisers's 13F filing for Q1 2026, filed 13 May 2026.